Better Home & Finance Deploys Poison Pill to Thwart Former CEO's Takeover Attempt
BETR is trading near its 52-week low of $11.431 (2.8% above the low) on elevated volume (2.0× avg).
Summary
Better Home & Finance has adopted a poison pill rights plan to block former CEO Vishal Garg's control bid, triggering at 15% ownership and expiring at the 2027 annual meeting.
Key Events · Corporate Governance and Compliance · BETR
-
Poison Pill Adopted
Effective August 20, 2026, the Special Committee adopted a limited-duration shareholder rights plan with a 15% beneficial ownership trigger threshold.
-
Rights Dividend Declared
Stockholders of record will receive one Class A, Class B, and Class C Right per respective share, payable August 31, 2026.
-
Exercise Terms
Each Right is exercisable at $65.00 per one one-thousandth of a Series A Junior Participating Preferred Share, with flip-in and flip-over provisions.
-
Expiration
The rights expire at the 2027 annual meeting of stockholders unless earlier redeemed or exchanged.
Analysis · BETR · Finance
To block former CEO Vishal Garg's attempt to seize control without paying a premium, the Special Committee has adopted a limited-duration shareholder rights plan with a 15% trigger. Any acquirer crossing that threshold faces severe dilution, effectively forcing them to negotiate with the board. This move marks a major escalation in the ongoing proxy fight and materially raises the cost of Garg's campaign.
How filings like this one have moved
In the 30 days to Aug 22, 2026, 37.5% of the 3496 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BETR was trading at $11.76 on NASDAQ in the Finance sector, with a market capitalization of approximately $220.4M. The 52-week trading range was $11.43 to $94.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.